2026 Q2 -tulosraportti
24 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 t sitten · MuokattuWhat's interesting about Novo right now is that the company might be more attractive as an investment because the strategy is not yet locked in. The market has already removed a large part of Novo's previous growth premium. The stock trades at a relatively low multiple, while the underlying business remains strong and generates a lot of money. The latest guidance-reset has also come out of the system. This means that as an investor, one does not necessarily need to believe that Novo will quickly return to high organic growth. What's crucial is rather that the current business continues to hold up while the long-term strategic solution is found. Here, the combination of Mike Doustdar and Lars Rebien Sørensen becomes interesting: Mike carries the present. Rebien holds the future. Mike can keep the commercial and operational machine running, implement savings, and ensure stability. Rebien and Fonden simultaneously have the authority to address the much larger question: What should Novo be heading towards the 2030s? This opens several paths to value creation. Novo can stabilize itself as an independent company. A credible new strategy can lift the multiple again. The portfolio can be strengthened through smaller acquisitions and partnerships. Or Fonden can choose a larger structural solution if it creates more value than continuing alone. It is therefore important that the investment case does not depend on a sale or a merger. It is the option on top of the case. In my view, DKK 280–350 is an accumulation zone where a significant part of the strategic uncertainty is already priced in. If Novo merely avoids new material damage and stabilizes earnings, there is a foundation under the case. If strategic clarity simultaneously brings Novo back towards, for example, 15–18× normalized earnings, a significant increase in value will occur without the need for explosive growth. A structural solution around, for example, DKK 500 would be further upside. This creates a somewhat unusual asymmetry: I don't necessarily buy Novo because I believe the current strategy will win. We are buying a very valuable business at a compressed price, while the controlling owner still has the opportunity to choose the future that creates the most value. That is actually what makes Novo more interesting now than a regular “going company” where both strategy and future direction are already locked in.
·10 t sittenWhile some investors choose to wait, I have used the recent price drops in Novo Nordisk to increase my position. What's interesting to me is not just the price drop itself, but the relationship between the lower price and the long-term potential I still see in the company. It therefore suits me perfectly when the market reacts negatively in the short term, if I simultaneously assess that the long-term investment case remains intact. No stock is without risk — not even Novo Nordisk. Therefore, for me, it's not about safety, but about probability and price. But good stocks bought at a significant discount are, in my world, a better bet — all else being equal. If the price recovers quickly, I can choose to sell the extra shares wholly or partially for a profit. For me, it's a disciplined way to exploit the market's short-term pessimism — knowing that the risk is still real. And finally, there are more countries and markets in the world than the USA
·11 t sittenThe stock market is closed. And yet two idiots have already spammed the day with 15 posts each. And we are only a little past noon. It never stops 30 totally contentless posts. And they have both appointed each other as supreme judges.
·12 t sittenWegovy Pill (at a low dose) we recently heard about, was to be tested. Several were a bit in doubt about why? Could the purpose be, "a pill for maintenance after weight loss"? Just a thought, after reading news today..
Yep - I will need that pill from summer 2027. I have been taking Wegovy since mid-January 2025 and lost 32 kilos. Need to lose approx 18 kilos more and look forward to a cheaper "maintenance pill" Of course, I also have Novo in my portfolio here on Nordnet- ·13 t sitten · MuokattuIf you, like me, are tired of the same 4-5 profiles who daily spam us with negativity, know-it-all attitudes, and ridiculous posts to get attention, then I would encourage you to no longer engage in dialogue with them! Instead, use my post below, copy and paste 👍 We've clearly understood that you're not a fan of Novo! But if you neither own the stock nor like the company, couldn't you try to find something else to do with your life?! The Novo forum doesn't need to be your full-time job 🤡 If it's too difficult, just use a 🤡 Emoji. Show that you support us who own Novo shares, us who are positive (though critical posts are fine, if they are well-written and not disparaging etc) Us who believe in Novo 📈
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
24 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sitten · MuokattuWhat's interesting about Novo right now is that the company might be more attractive as an investment because the strategy is not yet locked in. The market has already removed a large part of Novo's previous growth premium. The stock trades at a relatively low multiple, while the underlying business remains strong and generates a lot of money. The latest guidance-reset has also come out of the system. This means that as an investor, one does not necessarily need to believe that Novo will quickly return to high organic growth. What's crucial is rather that the current business continues to hold up while the long-term strategic solution is found. Here, the combination of Mike Doustdar and Lars Rebien Sørensen becomes interesting: Mike carries the present. Rebien holds the future. Mike can keep the commercial and operational machine running, implement savings, and ensure stability. Rebien and Fonden simultaneously have the authority to address the much larger question: What should Novo be heading towards the 2030s? This opens several paths to value creation. Novo can stabilize itself as an independent company. A credible new strategy can lift the multiple again. The portfolio can be strengthened through smaller acquisitions and partnerships. Or Fonden can choose a larger structural solution if it creates more value than continuing alone. It is therefore important that the investment case does not depend on a sale or a merger. It is the option on top of the case. In my view, DKK 280–350 is an accumulation zone where a significant part of the strategic uncertainty is already priced in. If Novo merely avoids new material damage and stabilizes earnings, there is a foundation under the case. If strategic clarity simultaneously brings Novo back towards, for example, 15–18× normalized earnings, a significant increase in value will occur without the need for explosive growth. A structural solution around, for example, DKK 500 would be further upside. This creates a somewhat unusual asymmetry: I don't necessarily buy Novo because I believe the current strategy will win. We are buying a very valuable business at a compressed price, while the controlling owner still has the opportunity to choose the future that creates the most value. That is actually what makes Novo more interesting now than a regular “going company” where both strategy and future direction are already locked in.
- ·10 t sittenWhile some investors choose to wait, I have used the recent price drops in Novo Nordisk to increase my position. What's interesting to me is not just the price drop itself, but the relationship between the lower price and the long-term potential I still see in the company. It therefore suits me perfectly when the market reacts negatively in the short term, if I simultaneously assess that the long-term investment case remains intact. No stock is without risk — not even Novo Nordisk. Therefore, for me, it's not about safety, but about probability and price. But good stocks bought at a significant discount are, in my world, a better bet — all else being equal. If the price recovers quickly, I can choose to sell the extra shares wholly or partially for a profit. For me, it's a disciplined way to exploit the market's short-term pessimism — knowing that the risk is still real. And finally, there are more countries and markets in the world than the USA
- ·11 t sittenThe stock market is closed. And yet two idiots have already spammed the day with 15 posts each. And we are only a little past noon. It never stops 30 totally contentless posts. And they have both appointed each other as supreme judges.
- ·12 t sittenWegovy Pill (at a low dose) we recently heard about, was to be tested. Several were a bit in doubt about why? Could the purpose be, "a pill for maintenance after weight loss"? Just a thought, after reading news today..Yep - I will need that pill from summer 2027. I have been taking Wegovy since mid-January 2025 and lost 32 kilos. Need to lose approx 18 kilos more and look forward to a cheaper "maintenance pill" Of course, I also have Novo in my portfolio here on Nordnet
- ·13 t sitten · MuokattuIf you, like me, are tired of the same 4-5 profiles who daily spam us with negativity, know-it-all attitudes, and ridiculous posts to get attention, then I would encourage you to no longer engage in dialogue with them! Instead, use my post below, copy and paste 👍 We've clearly understood that you're not a fan of Novo! But if you neither own the stock nor like the company, couldn't you try to find something else to do with your life?! The Novo forum doesn't need to be your full-time job 🤡 If it's too difficult, just use a 🤡 Emoji. Show that you support us who own Novo shares, us who are positive (though critical posts are fine, if they are well-written and not disparaging etc) Us who believe in Novo 📈
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
24 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sitten · MuokattuWhat's interesting about Novo right now is that the company might be more attractive as an investment because the strategy is not yet locked in. The market has already removed a large part of Novo's previous growth premium. The stock trades at a relatively low multiple, while the underlying business remains strong and generates a lot of money. The latest guidance-reset has also come out of the system. This means that as an investor, one does not necessarily need to believe that Novo will quickly return to high organic growth. What's crucial is rather that the current business continues to hold up while the long-term strategic solution is found. Here, the combination of Mike Doustdar and Lars Rebien Sørensen becomes interesting: Mike carries the present. Rebien holds the future. Mike can keep the commercial and operational machine running, implement savings, and ensure stability. Rebien and Fonden simultaneously have the authority to address the much larger question: What should Novo be heading towards the 2030s? This opens several paths to value creation. Novo can stabilize itself as an independent company. A credible new strategy can lift the multiple again. The portfolio can be strengthened through smaller acquisitions and partnerships. Or Fonden can choose a larger structural solution if it creates more value than continuing alone. It is therefore important that the investment case does not depend on a sale or a merger. It is the option on top of the case. In my view, DKK 280–350 is an accumulation zone where a significant part of the strategic uncertainty is already priced in. If Novo merely avoids new material damage and stabilizes earnings, there is a foundation under the case. If strategic clarity simultaneously brings Novo back towards, for example, 15–18× normalized earnings, a significant increase in value will occur without the need for explosive growth. A structural solution around, for example, DKK 500 would be further upside. This creates a somewhat unusual asymmetry: I don't necessarily buy Novo because I believe the current strategy will win. We are buying a very valuable business at a compressed price, while the controlling owner still has the opportunity to choose the future that creates the most value. That is actually what makes Novo more interesting now than a regular “going company” where both strategy and future direction are already locked in.
- ·10 t sittenWhile some investors choose to wait, I have used the recent price drops in Novo Nordisk to increase my position. What's interesting to me is not just the price drop itself, but the relationship between the lower price and the long-term potential I still see in the company. It therefore suits me perfectly when the market reacts negatively in the short term, if I simultaneously assess that the long-term investment case remains intact. No stock is without risk — not even Novo Nordisk. Therefore, for me, it's not about safety, but about probability and price. But good stocks bought at a significant discount are, in my world, a better bet — all else being equal. If the price recovers quickly, I can choose to sell the extra shares wholly or partially for a profit. For me, it's a disciplined way to exploit the market's short-term pessimism — knowing that the risk is still real. And finally, there are more countries and markets in the world than the USA
- ·11 t sittenThe stock market is closed. And yet two idiots have already spammed the day with 15 posts each. And we are only a little past noon. It never stops 30 totally contentless posts. And they have both appointed each other as supreme judges.
- ·12 t sittenWegovy Pill (at a low dose) we recently heard about, was to be tested. Several were a bit in doubt about why? Could the purpose be, "a pill for maintenance after weight loss"? Just a thought, after reading news today..Yep - I will need that pill from summer 2027. I have been taking Wegovy since mid-January 2025 and lost 32 kilos. Need to lose approx 18 kilos more and look forward to a cheaper "maintenance pill" Of course, I also have Novo in my portfolio here on Nordnet
- ·13 t sitten · MuokattuIf you, like me, are tired of the same 4-5 profiles who daily spam us with negativity, know-it-all attitudes, and ridiculous posts to get attention, then I would encourage you to no longer engage in dialogue with them! Instead, use my post below, copy and paste 👍 We've clearly understood that you're not a fan of Novo! But if you neither own the stock nor like the company, couldn't you try to find something else to do with your life?! The Novo forum doesn't need to be your full-time job 🤡 If it's too difficult, just use a 🤡 Emoji. Show that you support us who own Novo shares, us who are positive (though critical posts are fine, if they are well-written and not disparaging etc) Us who believe in Novo 📈
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt